Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
14.22
Nov 19 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
4.99B
Enterprise Value
4.39B
Income
-307.94M
Sales
0.00M
Book/sh
2.62
Cash/sh
1.83
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
103
IPO
Jul 16, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
5.43
P/C
7.75
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.89
Current Ratio
14.89
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-1.00
EPS next Y
-0.75
EPS next Q
-0.15
EPS this Y
-131.50%
EPS next Y
26.59%
EPS next 5Y
-
EPS past 3/5Y
39.56% 12.46%
Sales past 3/5Y
- -
EPS Y/Y TTM
-120.99%
Sales Y/Y TTM
-
EPS Q/Q
-38.18%
Sales Q/Q
-
Insider Own
29.33%
Insider Trans
0.00%
Inst Own
71.76%
Inst Trans
1.35%
ROA
-43.39%
ROE
-48.70%
ROIC
-32.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-4.13%
SMA50
-4.00%
SMA200
-7.22%
Trades
Shs Outstand
350.24M
Shs Float
248.03M
52W High
24.28 -41.43%
52W Low
2.75 417.09%
Volatility
9.95% 8.41%
ATR (14)
1.24
RSI (14)
46.06
Beta
0.65
Rel Volume
0.00
Avg Volume
5.10M
Volume
0
Perf Week
-9.89%
Perf Month
-1.86%
Perf Quarter
-19.34%
Perf Half Y
22.53%
Perf YTD
282.26%
Perf Year
415.22%
Perf 3Y
520.96%
Perf 5Y
-21.13%
Perf 10Y
-
Prev Close
14.22
Price
14.22
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$24.64
Implied Upside
+73.3%
Analysts11incl. previous ratings
Rating Distribution9 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 17, 2026Initiated
LLeerink
Outperform$35+146.1%
Jun 04, 2026Upgrade
BAC logoBBofA Securities
Underperform → Neutral$16+12.5%
Jan 27, 2026Resumed
MFG logoMMizuho
Outperform$16+12.5%
Jan 07, 2026Initiated
PPiper Sandler
Overweight$5-64.8%
Oct 16, 2025Initiated
SF logoSStifel
Buy$4-71.9%
Sep 03, 2025Downgrade
BAC logoBBofA Securities
Buy → Underperform
Aug 18, 2025Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$2-85.9%
Mar 26, 2025Initiated
RJF logoRRaymond James
Outperform$5-64.8%
Nov 18, 2024Initiated
JEF logoJJefferies
Buy$6-57.8%
Mar 11, 2024Initiated
CCapitalOne
Overweight$8-43.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Erasca FoundationFoundationNov 16 '26Proposed Sale15.518,333129,256Nov 16 12:45 PM
Erasca FoundationFoundationOct 15 '26Proposed Sale14.688,333122,353Oct 15 12:18 PM
Erasca FoundationFoundationSep 15 '26Proposed Sale15.978,333133,094Sep 15 04:46 PM
Erasca FoundationFoundationAug 17 '26Proposed Sale18.298,333152,419Aug 17 02:13 PM
Erasca FoundationFoundationJul 21 '26Proposed Sale18.928,333157,638Jul 21 04:05 PM
Erasca FoundationFoundationJun 15 '26Proposed Sale14.108,333117,477Jun 15 05:52 PM
Erasca FoundationFoundationMay 15 '26Proposed Sale10.148,33384,528May 15 04:46 PM
Erasca FoundationFoundationApr 15 '26Proposed Sale18.108,333150,843Apr 15 05:06 PM
Garner EbunChief Legal OfficerApr 01 '26Option Exercise1.7080,000136,000105,076Apr 03 09:00 AM
Garner EbunChief Legal OfficerApr 01 '26Sale16.4080,0001,312,00025,076Apr 03 09:00 AM
Ebun GarnerOfficerApr 01 '26Proposed Sale16.4080,0001,312,355Apr 01 02:19 PM
Erasca FoundationFoundationMar 16 '26Proposed Sale14.028,333116,855Mar 16 02:38 PM
Morris ShannonChief Medical OfficerMar 04 '26Option Exercise1.7020,00034,00020,000Mar 06 09:00 AM
Morris ShannonChief Medical OfficerMar 04 '26Sale15.0420,000300,7600Mar 06 09:00 AM
Shannon MorrisOfficerMar 04 '26Proposed Sale15.0420,000300,769Mar 04 05:38 PM
Erasca FoundationFoundationFeb 17 '26Proposed Sale11.918,33399,245Feb 17 02:27 PM
Erasca FoundationFoundationJan 15 '26Proposed Sale8.238,33368,574Jan 15 10:43 AM
Garner EbunGeneral Counsel & Corp. Sec.Jan 07 '26Option Exercise1.70120,000204,000145,076Jan 08 09:20 PM
Garner EbunGeneral Counsel & Corp. Sec.Jan 07 '26Sale5.59120,000670,81225,076Jan 08 09:20 PM
Ebun GarnerOfficerJan 07 '26Proposed Sale5.59120,000670,809Jan 07 03:58 PM
Erasca FoundationFoundationDec 15 '25Proposed Sale3.658,33330,439Dec 15 08:11 PM
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
Co-FounderDr. Jonathan E. Lim M.D.
CFO & Chief Business OfficerDr. David M. Chacko M.D.
Chairman of Research & DevelopmentDr. Michael D. Varney Ph.D.
Ph.D.Dr. Shannon R. Morris M.D.
Senior Vice President of AccountingMs. Alison Tjosvold Milhous